IQVIA
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1.55% less ownership
Funds ownership: 86.21% [Q3] → 84.66% (-1.55%) [Q4]
6% less funds holding
Funds holding: 1,044 [Q3] → 982 (-62) [Q4]
19% less capital invested
Capital invested by funds: $37.1B [Q3] → $30.2B (-$6.92B) [Q4]
24% less repeat investments, than reductions
Existing positions increased: 320 | Existing positions reduced: 423
25% less first-time investments, than exits
New positions opened: 128 | Existing positions closed: 170
29% less funds holding in top 10
Funds holding in top 10: 14 [Q3] → 10 (-4) [Q4]
36% less call options, than puts
Call options by funds: $165M | Put options by funds: $260M
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$210
13%
upside
Avg. target
$243
31%
upside
High target
$270
45%
upside
9 analyst ratings
7 positive
78%
2 neutral
22%
0 negative
0%
Citigroup Patrick Donnelly 26% 1-year accuracy 8 / 31 met price target | 13%upside $210 | Neutral Maintained | 4 Mar 2025 |
JP Morgan Anne Samuel 51% 1-year accuracy 18 / 35 met price target | 25%upside $232 | Overweight Maintained | 18 Feb 2025 |
Morgan Stanley Tejas Savant 21% 1-year accuracy 4 / 19 met price target | 34%upside $250 | Overweight Maintained | 11 Feb 2025 |
RBC Capital Sean Dodge 39% 1-year accuracy 14 / 36 met price target | 45%upside $270 | Outperform Reiterated | 10 Feb 2025 |
Truist Securities Jailendra Singh 46% 1-year accuracy 16 / 35 met price target | 41%upside $263 | Buy Reiterated | 10 Feb 2025 |
Financial journalist opinion
Based on 7 articles about IQV published over the past 30 days
Neutral
Business Wire
1 week ago
IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the “Leaders” category of the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment. IDC, a global provider of market intelligence, says in its report: “Consider IQVIA when s.
Positive
Zacks Investment Research
2 weeks ago
IQVIA Gains From Diversified Client Base Despite Low Liquidity Woes
The IQV stock benefits from its healthcare-centric IT infrastructure across the globe and a treasure trove of data distinguishing it from its competitors.
Neutral
Business Wire
2 weeks ago
IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Laboratories, a leading global drug discovery and development laboratory services organization, announces the launch of Site Lab Navigator, an advanced suite of solutions that automates and streamlines lab workflows for clinical trial sponsors and investigator sites. At the core of Site Lab Navigator is a new, innovative e-Requisition solution, which allows investigator sites to submit requisitions and manage lab specimens electronically, eli.
Neutral
Business Wire
3 weeks ago
Global Healthy Living Foundation and IQVIA Institute Report Millions of Adult Vaccines Likely Missed When States Restrict Pharmacist Participation
UPPER NYACK, N.Y.--(BUSINESS WIRE)--When pharmacists can't give adult vaccinations, millions of people go without them.
Positive
Zacks Investment Research
3 weeks ago
IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
Business Wire
3 weeks ago
IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries, today announced that IQVIA AI Assistant has been awarded a 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, IQVIA AI Assistant revolutionizes insight generation by providing rapid, relevant and precise answers to complex business questio.
Neutral
Business Wire
4 weeks ago
IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the TD Cowen Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a lead.
Neutral
Business Wire
1 month ago
IQVIA Releases 2024 Sustainability Report
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has published its 2024 Sustainability Report. The report details IQVIA's sustainability achievements consistent with its mission to accelerate innovation for a healthier world. “IQVIA combines technology and scientific expertise with our unique information assets and Healthcare-gr.
Neutral
Zacks Investment Research
1 month ago
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
Positive
Seeking Alpha
1 month ago
IQVIA: Revenues, Net Profit Margin, And A Positive Long-Term Outlook Will Pave The Way
IQVIA has seen an increase of 58.97% in its revenues since 2017. In addition, its net profit margin has strengthened since 2018. The CRO market expects to grow at a 7.42% CAGR between 2024 and 2033, which indicates that the Research & Development Solutions segment of IQVIA will have a positive outlook. IQVIA has an enormous dataset, with 1,200 million registers. This dataset has been crucial for developing artificial intelligence and data analytics solutions in the upcoming years.
Charts implemented using Lightweight Charts™